Government rules changed to ensure availability of GLP-1 RAs 5 June 2024 From this week, Government rules have been changed to ensure medicines like Ozempic and Trulicity are available for the people who need them most. These medicines are called glucagon-like peptide 1 receptor agonists or GLP-1 RAs. When the government began subsidising GLP-1 RAs they could only be available if you were being treated with other diabetes medicines (like metformin, insulin, etc) and the other medicines weren’t working to reduce your blood glucose, or you had a reaction. However, data shows that people were being prescribed GLP-1 RAs outside of these rules. In order to deal with this, the rules have been changed to: Increase access by only requiring one other medicine to have been tried (e.g. metformin), and Require doctors to get phone authorization before they can prescribe GLP-1 RAs to new users. If you’re already on Ozempic or another GLP-1 RA and it is funded through the government, these new rules shouldn’t affect you. We know that GLP-1 RAs are in short supply, and we don’t think these rules will have an immediate effect on your ability to get access to these medicines. More information is available from the PBS website.
Media releases 30 April 2025 Melbourne to host International Diabetes Congress amid rising health crisis In a major win for Australia’s diabetes community, the International Diabetes Federation Western Pacific Region (IDF WPR) Congress 2026 will... Continue Reading
Media releases 28 April 2025 New nib foundation partnership to enhance diabetes care for people living with disability A groundbreaking new partnership between Diabetes Australia and nib foundation will improve the lives of people living with both diabetes... Continue Reading
Media releases 8 April 2025 New data reveals diabetes prevalence in Australia may be 35% higher New research from the University of Sydney reveals that the number of Australians living with diabetes may be up to... Continue Reading